MCP-1/CCL2 levels in MS have been found to be decreased in the CSF, especially during active disease stages, and correlated with indices of intrathecal IgG production and CSF levels of neurofilament light protein (NFL) [71]. This evidence concerns the gene NEFL and myeloid sarcoma.